Innovator IBD 50 ETF Achieves 5-Star Rating from Morningstar

Innovator Capital Management, LLC (Innovator) announced today that the Innovator IBD® 50 ETF (FFTY) has earned a Morningstar 5-Star Rating out of 18 ETFs based on risk-adjusted returns for the three-year period ending August 31, 2018.

FFTY, which is categorized by Morningstar as a Mid-Cap Growth ETF, has outperformed the Morningstar Mid Growth Index by 4.05% per year1 for the three year period ended August 31, 2018. The Fund returned 14.93% YTD, and has achieved a three-year annualized return of 19.54% (NAV) through August 31, 2018.

“We are very pleased to see the Innovator IBD® 50 ETF (FFTY) achieving a 5-Star Morningstar Rating,” said Bruce Bond, Chief Executive Officer of Innovator. “Investor’s Business Daily has been a great partner for us, and their demonstrated ability for identifying high-quality growth companies continues to resonate with investors.”

FFTY provides exposure to a tactical, high-conviction portfolio of the 50 top-ranked growth stocks according to Investor’s Business Daily’s CAN SLIM® Investing System.

“The IBD® 50 has a long-term record of outperformance since its inception,” added Chris Gessel, Chief Content Officer of IBD. “We are delighted that investors have a convenient way to capitalize on this strategy using the Innovator IBD® 50 ETF.”